论文部分内容阅读
近年来,随着类风湿性关节炎发病机制及某些致炎因子的发现,出现了一系列新药。环氧合酶-Ⅱ特异性抑制剂与传统的非甾体类抗炎药相比具有疗效好、副作用小的优点;早期联合使用改变病情性抗风湿药在近期内有较好的临床疗效。此外重组可溶性肿瘤坏死因子受体融合蛋白 (etanercept)、人体抗肿瘤坏死因子-α单克隆抗体(adalimumab)和阿那白滞素(anakinra)等生物学治疗及中药治疗均显示了新的治疗前景。
In recent years, with the pathogenesis of rheumatoid arthritis and the discovery of certain inflammatory factors, a series of new drugs have emerged. Cyclooxygenase-Ⅱ specific inhibitors with traditional non-steroidal anti-inflammatory drugs compared with good efficacy, the advantages of small side effects; combination of early changes in disease-resistant antirheumatic drugs in the near future have a good clinical effect. In addition, biological therapy such as recombinant soluble tumor necrosis factor receptor fusion protein (etanercept), human anti-tumor necrosis factor-α monoclonal antibody (analbin) and anakinra and traditional Chinese medicine have shown a new therapeutic prospect .